Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 48
- Registration Number
- NCT04268394
- Locations
- 🇬🇧
Richmond Pharmacology Limited, London, United Kingdom
Antecedent Metabolic Health and Metformin Aging Study
- Conditions
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 148
- Registration Number
- NCT04264897
- Locations
- 🇺🇸
University of Wisconsin-Madison, Madison, Wisconsin, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma Shared Clinical and Translational Resources, Oklahoma City, Oklahoma, United States
Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2023-01-18
- Target Recruit Count
- 30
- Registration Number
- NCT04248998
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT04231435
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Metformin for Abdominal Aortic Aneurysm Growth Inhibition
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Uppsala University Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT04224051
- Locations
- 🇸🇪
Uppsala University Hospital, Uppsala, Sverige, Sweden
MeDiGes Study: Metformine Use in Gestational Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2020-05-15
- Target Recruit Count
- 200
- Registration Number
- NCT04222348
Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 114
- Registration Number
- NCT04221750
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States
Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD
- Conditions
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 18
- Registration Number
- NCT04220021
- Locations
- 🇺🇸
UF Health at the University of Florida, Gainesville, Florida, United States
A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM
- Conditions
- Interventions
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT04218734
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)
- Conditions
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2022-08-30
- Target Recruit Count
- 6
- Registration Number
- NCT04209075
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.